title: [Dermatologic therapy in pregnancy].
abstract: Pharmacologic therapy of a pregnant patient requires particular care in selecting the active substances to be used, their dosage and administration. The teratogenic risk and the therapeutic benefit must be carefully weighed for the mother and possibly also for the child, and attention paid to the special precautions and documentation obligations of off-label applications. This article addresses the general aspects of benefit-risk evaluation, provides an opinion on the teratogenic potency of dermatologically relevant medications, formulates recommendations for frequent general dermatological indications and lists additional possible information sources for special case constellations.
authors.affiliation: Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Martin Luther Universität Halle-Wittenberg, Ernst-Kromayer-Str. 5, 06097, Halle. johannes.wohlrab@medizin.uni-halle.de
authors.forename: J
authors.initials: J
authors.lastname: Wohlrab
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents